Jane E. Wilcox

Functional High Throughput Drug Screening Reveals Cyproheptadine as a Novel Treatment for LMNA -related Cardiomyopathy

This paper uses patient-derived hiPSC-CMs to identify cyproheptadine as a therapeutic for LMNA-related DCM by revealing shared and variant-specific disease mechanisms.

Implementing Precision Medicine for Dilated Cardiomyopathy: Insights from The DCM Consortium

This study identifies barriers and needs for genetic evaluation in dilated cardiomyopathy through a survey and discussion with cardiologists, highlighting the need for improved reimbursement, education, and infrastructure.

Differences in Cardiac Mechanics among Genetically At-Risk First-Degree Relatives: The DCM Precision Medicine Study

The paper examines cardiac mechanics in genetically at-risk first-degree relatives of DCM patients, finding that older relatives with variants of uncertain significance or pathogenic variants have reduced global longitudinal strain.